Paridiprubart is a Monoclonal Antibody owned by Edesa Biotech, and is involved in 5 clinical trials, of which 3 were completed, and 2 are ongoing.
EB-05 (NI-0101) acts as toll-like receptor 4 (TLR4) antagonist. NI-0101 binds to an epitope on TLR4 which interferes with its dimerization required for intracellular signaling and induction of numerous pro-inflammatory pathways. TLR4 activates NF-kappa B-dependent transcription of inflammatory cytokine genes in the diseased condition. The drug candidate blocks at the level of signal transduction for any ligand source and treats the condition.
The revenue for Paridiprubart is expected to reach a total of $133m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Paridiprubart NPV Report.
EB-05 (NI-0101) is under development for the treatment of allergic contact dermatitis, acute respiratory distress syndrome (ARDS) associated with COVID-19 pneumonia caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and unspecified disease. The drug candidate is administered intravenously. It is a humanized monoclonal antibody (mAb) targeting human Toll-like receptor 4 (TLR4). It was under development for the treatment of rheumatoid arthritis.
Edesa Biotech Overview
Edesa Biotech is a clinical-stage biopharmaceutical and healthcare company, which focuses on the development of gastrointestinal and dermatological diseases, including alternatives to topical steroids. The company’s clinical product pipeline includes EB01, which is a novel sPLA2 inhibitor (non-steroidal anti-inflammatory molecule) for the topical treatment of chronic allergic contact dermatitis (ACD) and EB02, which is a novel sPLA2 inhibitor for the treatment of hemorrhoids in adults. In addition, its two lead product candidates, EB01 and EB05 are in clinical studies. Edesa Biotech’s EB05 product is a monoclonal antibody therapy that we are developing as a treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. It has operations in Canada and the US. Edesa Biotech is headquartered in Markham, Ontario, Canada.
The operating loss of the company was US$23.7 million in FY2021, compared to an operating loss of US$6.4 million in FY2020. The net loss of the company was US$13.3 million in FY2021, compared to a net loss of US$6.4 million in FY2020.
Quick View – Paridiprubart
|Highest Development Stage|